Supplemental Materials: Th17/IL-17-axis in paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome as potential therapeutic targets: A prospective cohort study

Supplemental figure 1. Clinical manifestations of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PNP/PAMS), including: A. lichenoid dermatitis, B. blisters with erosions, C. oral erosions, D. vulvar erosions, E. ocular erosions, and F. penile erosions. Supplemental figure 2. Hematoxylin and eosin stain showed suprabasal acantholysis along with perivascular lymphocytic infiltrate with scattered neutrophils.Supplemental figure 3. Direct immunofluorescence stains demonstrated positive immunostaining against immunoglobulin G and/or C3 depositions on intraepidermal spaces and/or dermo-epidermal junctions.Supplemental figure 4. Enzyme-linked immunosorbent assay detecting autoantibodies against self-antigens within the plasma of patients with PNP/PAMS. BP, Bullous pemphigoid; DSG, Desmoglein.Supplemental figure 5. Hierarchical cluster heatmap of Nanostring gene expression of patients with PNP/PAMS and healthy controls (HC).Supplemental figure 6. A. Refractory painful mucosal erosions that require nasoduodenal tube placement for feeding; B. Healed erosions after anti-interleukin-17 receptor A (brodalumab) treatment for three weeks.Supplemental figure 7. PNP/PAMS lesions before (A) and after (B) two doses of brodalumab treatment.Supplemental Methods.